Approximately one-third of the world's population is estimated to be infected with latent *Mycobacterium tuberculosis*, and approximately 10% of these individuals are expected to go on to develop active disease ([@b1-idmm-25-281]). This makes treatment for latent tuberculosis (TB) infection (LTBI) an important strategy for TB control programs. However, the effectiveness of LTBI treatment depends on treatment adherence. Overall, treatment adherence has ranged from 22% to 90% in various risk groups ([@b2-idmm-25-281]).

In countries with low TB incidence, the challenge of effective LTBI treatment lies in high-risk groups and settings. Injection drug use, excessive alcohol use, unemployment and homelessness have been associated with failure to complete preventive treatment ([@b2-idmm-25-281]). Strategies that have demonstrated some effectiveness in improving adherence within these high-risk groups include directly observed therapy, monetary incentives, educational programs or some combination thereof ([@b2-idmm-25-281]--[@b10-idmm-25-281]). Additionally, shorter-course treatment regimens have been increasingly associated with improved adherence ([@b3-idmm-25-281]).

A limited number of studies have been published that examine treatment completion rates and interventions used to increase treatment completion within an inner-city population ([@b3-idmm-25-281]). The purpose of the present study was to determine the rate of LTBI treatment completion within an inner-city population in Edmonton, Alberta, and to identify factors that correlate with treatment completion.

METHODS
=======

Study setting and population
----------------------------

Edmonton is a northern Canadian city with a population of 1,024,820; 18.5% of the population are immigrants ([@b11-idmm-25-281]). The homeless population is estimated to be 3079 and is concentrated in the inner city of Edmonton ([@b12-idmm-25-281]). A central inner-city health clinic provides multidisciplinary care to this population. A significant proportion of patients are HIV- and/or hepatitis C-infected, homeless or underhoused, working poor or unemployed, report substance use, and are Aboriginal or recent immigrants. The clinic is located in the inner city and provides further outreach services within the community to locate patients (including to local shelters, drop-ins, homes, etc). The clinic model focuses on intensive outreach case management of all cases of active TB and LTBI, focusing on tracking and adherence-coaching interventions, education, nonmonetary incentives and health promotion strategies aimed at improving barriers to accessing health care and addressing social determinants of health.

Demographic and clinical characteristics
----------------------------------------

A retrospective review of all patients diagnosed with LTBI between January 1, 2005 and December 31, 2010, at the inner-city outreach TB clinic was completed. Demographic, clinical and treatment data were extracted from the Integrated Public Health Information System and from patient health care charts. Patients were excluded from the study if a LTBI treatment regimen other than isoniazid (INH) or rifampin was used.

Definitions
-----------

The diagnosis of LTBI was made in accordance with criteria described in the Canadian Tuberculosis Standards (6th edition) ([@b9-idmm-25-281]). Completion of LTBI was defined by completing a specified number of doses within a specified time period for each regimen. Completion of a nine-month daily INH regimen was defined as 270 doses within 12 months, and completion of a nine-month, twice-per-week INH regimen was defined as 76 doses within 12 months. Completion of a four-month rifampin regimen was defined as 120 doses within a six-month period. Completion of a six-month rifampin and INH twice weekly regimen was defined as 52 doses within a nine-month period ([@b13-idmm-25-281]). TB public health nurses assessed compliance of self-administered treatment based on patient self-reporting and prescription refills.

Data analysis
-------------

Frequencies and proportions were calculated for categorical variables. The median and interquartile range was calculated for continuous variables. The χ^2^ or Fisher's exact (depending on cell size) and the Mann-Whitney test were used to detect differences between individuals who had completed treatment and those who had not. Bivariate logistic regression was completed using variables significant (P\>0.10) at the univariate level. Analyses were completed using SPSS version 19 (IBM Corporation, USA). The present study obtained ethics approval (ID Pro00018631) from the Health Research Ethics Board, a conjoint University of Alberta, Alberta Health Services and Covenant Health Research Ethics Boards designated under the Health Information Act.

RESULTS
=======

A total of 85 patients attending the inner-city TB program were identified to have LTBI and offered treatment between January 1, 2005 through to December 31, 2010. Of these, 90.6% (n=77) accepted treatment. There were no significant differences in sex, ethnicity, homelessness, or alcohol and drug use between those who accepted treatment and those who refused. Of the 77 patients who were started on treatment for LTBI, tuberculin skin test was positive in 72 (94.7%). Of the five remaining patients, the diagnosis of LTBI was based on positive interferon gamma release assay (n=1) and abnormal chest x-ray compatible with previous granulomatous infection (n=4).

[Table 1](#t1-idmm-25-281){ref-type="table"} shows the demographic and clinical characteristics of the study population. Overall, patients were predominantly male (n=48 \[62.3%\]), Canadian-born Aboriginal (n=32 \[45.1%\]) or foreign-born (n=23 \[32.4%\]), and unemployed (n=58 \[69.4%\]). In addition, some patients were homeless (n=7 \[9.1%\]), incarcerated at the start of treatment (n=13 \[17.1%\]), and reported drug and alcohol use (n=18 \[25.7%\] and n=25 \[34.7%\], respectively).

The most common reasons for LTBI treatment included contact with a TB case (n=33 \[42.9%\]), being immunosuppressed (n=32 \[41.6%\]), tuberculin skin test conversion (n=15 \[19.5%\]) and history of incarceration (n=14 \[18.2%\]). In addition, chest x-ray abnormalities were present in 27.3% (n=21) of patients; 21.1% (n=16) of patients had 'low-risk scars' defined by the presence of granuloma and 5.7% (n=5) of patients had 'high-risk' scars defined by upper-lobe fibronodular changes. Nearly one-third (n=24 \[31.2%\]) of patients were HIV positive and two (2.6%) had a history of receiving preventive treatment for LTBI.

Three-quarters of patients (n=60 \[77.9%\]) were treated using a nine-month INH regimen, 9.1% (n=7) of patients were treated using a four-month rifampin regimen, and a combined six-month INH and rifampin regimen was used to treat 13.0% (n=10) patients. Medication delivery was supported by directly observed therapy in 59.5% (n=44) of patients and, in addition, one-third of patients (n=23 \[32.4%\]) also received nonmonetary incentives (food supplements, bus tickets or taxi chits to attend appointments) toward treatment completion.

Of the 77 patients that started LTBI treatment, 74% (n=57) completed treatment. The majority of patients who did not complete their LTBI treatment refused or were noncompliant (n=12 \[60%\]). The remaining 40% of patients experienced side effects (n=5 \[25%\]), relocated (n=2 \[10%\]) or were medically advised to stop treatment (n=1 \[5%\]) with the reason undocumented. Of the five patients who experienced side effects, three had elevated liver enzyme levels and two patients developed a rash.

Through univariate analysis, homelessness was the only variable that was significantly associated with not completing treatment (OR 8.0 \[95% CI 1.4 to 45.6\]; P=0.019, [Table 1](#t1-idmm-25-281){ref-type="table"}). When drug use was controlled for in the regression model, homelessness remained the only significant factor (adjusted OR 6.5 \[95% CI 1.1 to 38.8\]). Incarceration and homeless were mutually exclusive categories and, therefore, none of the homeless populations were on LTBI treatment due to incarceration; thus, this variable was not included in the model. The number of homeless patients in the sample was small (n=7); however, they were more likely to be immunosuppressed (85.7% versus 40.0%; P=0.04), and HIV positive (85.7% versus 25.7%; P=0.003). They were also more likely to use alcohol (71.4% versus 30.8%; P=0.045) and although not statistically significant, to use drugs (57.1% versus 22.2%; P=0.067). Of the seven homeless patients, five did not complete treatment due to noncompliance (n=3), elevated liver enzyme levels (n=1) and medical advice (n=1).

DISCUSSION
==========

The present study, conducted at an inner-city health clinic in Edmonton, Alberta, demonstrates that high completion rates of LTBI treatment can be achieved in an inner-city population, with nearly three-quarters (n=57 \[74%\]) of patients completing their treatment. Although our completion rate is comparable with or better than that described within the general population ([@b3-idmm-25-281],[@b8-idmm-25-281],[@b14-idmm-25-281]--[@b17-idmm-25-281]), it exceeds the rates reported among inner-city patients (20% to 44.6%) in previous studies ([@b3-idmm-25-281],[@b4-idmm-25-281],[@b17-idmm-25-281]).

In our study, the only factor to be negatively associated with treatment completion was homelessness. This finding has been previously documented in other inner-city populations ([@b3-idmm-25-281],[@b4-idmm-25-281],[@b16-idmm-25-281]--[@b18-idmm-25-281]). A recent review of the annual TB incidence associated with homelessness in the United States identified an approximately 10-fold higher rate compared with the general population. Additionally, homeless TB patients were found to have twice the odds of not completing treatment due to being lost to follow-up, having moved or refusing treatment ([@b19-idmm-25-281]).

Homelessness has been associated with individual risk factors that can increase the risk of the development of active TB such as malnutrition, smoking, diabetes, HIV infection and alcohol abuse ([@b9-idmm-25-281],[@b20-idmm-25-281],[@b21-idmm-25-281]). The homeless population in our study was more likely to be HIV positive, use alcohol and, although not statistically significant, use drugs. Homeless TB patients also tend to seek care when disease is advanced and highly contagious, with subsequent exposure of a large number of vulnerable individuals to the disease through the shelter system and other sites of aggregation. TB genotyping data also suggest that homelessness is associated with greater risk of transmission ([@b19-idmm-25-281],[@b22-idmm-25-281],[@b23-idmm-25-281]). Thus, identification and treatment of homeless individuals with LTBI may provide the greatest opportunity to prevent future cases in this population and underscores the importance of public health outreach strategies ([@b19-idmm-25-281]).

Multiple barriers exist for homeless populations in accessing health care services, despite the fact that Canada has a system of universal health care insurance ([@b24-idmm-25-281]). First, primary concerns for homeless populations often include housing, food security, employment and income support, rather than their health status ([@b25-idmm-25-281]--[@b27-idmm-25-281]). These competing priorities may impede homeless individuals from using health care services, particularly those perceived as optional or even potentially harmful, as is the case for LTBI treatment. Second, a lack of awareness, information and knowledge about health conditions and available services significantly challenge access to health care and other social services ([@b7-idmm-25-281],[@b28-idmm-25-281]). Finally, homeless populations experience a significant amount of stigmatization and discrimination within the health care system, leading to a feeling of mistrust for health care providers ([@b28-idmm-25-281]).

A systematic review of adherence studies in the United States and Canada noted suboptimal completion and adherence rates in all high-risk groups; interventions aimed at improving adherence in these groups have been inconsistent ([@b2-idmm-25-281]). Patient characteristics associated with improved adherence include recent exposure to TB, social support and higher level of education ([@b2-idmm-25-281]). Programmatic strategies that have demonstrated some effectiveness in improving adherence within high-risk groups include directly observed therapy, monetary incentives, educational programs, shorter-course treatment regimens or some combination thereof ([@b2-idmm-25-281]--[@b10-idmm-25-281]).

With the exception of monetary incentives, which were not used in our clinic, none of these interventions were significantly associated with increased rates of treatment completion. We attribute our high rate of LTBI completion among this inner-city population, in large part, to the intensive case management model of our clinic, which provides holistic care to the patient to ensure they have consistent access to health care. The model of our clinic seeks to consider the identified barriers to care for homeless populations as well as identified programmatic factors for improving treatment adherence such as directly observed therapy, education and shorter-course regimens.

Our clinic is located centrally at an inner-city community health centre and has an outreach nurse who provides intensive outreach case management focusing on tracking, adherence coaching, education, nonmonetary incentives (including transportation vouchers and dietary supplements), and health promotion strategies aimed at improving barriers to accessing health care and addressing social determinants of health. Additionally, the clinic provides on-site appointments with a TB physician, and laboratory and x-ray access with extended hours of operation. The outreach model also aims to include partnerships in providing TB care within inner-city agencies and nongovernmental organizations through providing onsite educational and screening programs. In this setting, it is easier to establish a trusting relationship with the TB nurse provider to support the client population in following recommendations and adhering to treatment regimes. Moreover, the outreach model creates a 'therapeutic community' and a safe and supportive environment for its members, enabling the community of inner-city agencies and nongovernmental organizations to actively support clients in keeping appointments and adhering to the recommended treatment regimen, thus positively impacting treatment adherence. Such models of intensive case management have been shown to have some success with TB screening and treatment and requires further exploration to improve health care outcomes in this 'hard-to-reach' demographic ([@b7-idmm-25-281],[@b29-idmm-25-281],[@b30-idmm-25-281]). Although, programmatically, delivery of care in the out-reach model is the same for every patient, the transient nature of the homeless population makes it difficult to consistently track and locate these individuals. As a result, this population does not utilize the service adequately. This highlights the need to improve health care and housing strategies for the homeless.

Our study had several limitations. The small number of cases among homeless individuals limits the strength of our findings. The small sample size also limits the generalizability of our findings to other populations. Despite our success in treatment completion, the transient nature of homeless populations remains a challenge to our ability to provide intensive case management and tracking which is the cornerstone of our outreach strategy. This challenge underscores the need for innovative health care delivery strategies that meet the needs of homeless populations, the need for further studies addressing adherence interventions in this population and the need for greater efforts to decrease homelessness.

CONCLUSION
==========

Improved treatment completion rates of LTBI among an inner-city cohort of patients is possible with intensive case management combining tracking, education, incentives and health promotion. However, homelessness remains a significant barrier, suggesting the need for improved health care delivery and housing strategies for this population.

###### 

Demographic, clinical and treatment characteristics according to latent tuberculosis (TB) infection (LTBI) treatment completion status in Edmonton, Alberta, n=77

                                                                            **LTBI treatment status[\*](#tfn2-idmm-25-281){ref-type="table-fn"}**   **P**                       
  ------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------- ------------- ----------
  Demographic characteristics                                                                                                                                                   
    Male sex                                                                15 (75.0)                                                               33 (57.9)     48 (62.3)     0.17
    Median age, years (interquartile range)                                 47 (44--52)                                                             45 (35--51)   46 (37--52)   0.23
    Currently employed                                                      5 (31.3)                                                                14 (30.4)     19 (30.6)     0.95
    Currently homeless                                                      5 (25.0)                                                                2 (3.5)       7 (9.1)       **0.01**
  Ethnicity                                                                                                                                                                     
    Canadian-born non-Aboriginal                                            4 (22.2)                                                                12 (22.6)     16 (22.5)     1.00
    Canadian-born Aboriginal                                                8 (44.4)                                                                24 (45.3)     32 (45.1)     
    Foreign born                                                            6 (33.3)                                                                17 (32.1)     23 (32.4)     
  Lifestyle                                                                                                                                                                     
    Current alcohol use                                                     9 (47.4)                                                                16 (30.2)     25 (34.7)     0.18
    Current drug use                                                        8 (40.0)                                                                10 (20.0)     18 (25.7)     0.08
  Medical history                                                                                                                                                               
    Previous LTBI treatment                                                 1 (5.0)                                                                 1 (1.8)       2 (2.6)       0.46
    Positive TB skin test                                                   19 (95.0)                                                               53 (94.6)     72 (94.7)     1.00
    HIV positive                                                            6 (30.0)                                                                18 (31.6)     24 (31.2)     0.90
  Chest x-ray abnormalities                                                                                                                                                     
    Absent                                                                  13 (65.0)                                                               43 (76.8)     56 (73.7)     0.13
    Low-risk lung scars                                                     7 (35.0)                                                                9 (16.1)      16 (21.1)     
    High-risk lung scars                                                    0                                                                       4 (7.1)       5 (5.7)       
  Reasons for LTBI treatment^[†](#tfn3-idmm-25-281){ref-type="table-fn"}^                                                                                                       
    Recent contact to TB                                                    11 (55.0)                                                               22 (38.6)     33 (42.9)     0.20
    Communal living                                                         1 (5.0)                                                                 0             1 (1.3)       0.26
    Tuberculin skin test conversion                                         2 (10.0)                                                                13 (22.8)     15 (19.5)     0.33
    Incarceration                                                           1 (5.0)                                                                 13 (22.8)     14 (18.2)     0.10
    High-risk employment setting                                            2 (10.0)                                                                4 (7.0)       6 (7.8)       0.65
    Recent immigration (\<2 years)                                          1 (5.0)                                                                 0             1 (1.3)       0.26
    Immunosuppressed                                                        8 (40.0)                                                                24 (42.1)     32 (41.6)     0.87
    Lung scar                                                               7 (35.0)                                                                13 (22.8)     20 (26.0)     0.29
  Treatment                                                                                                                                                                     
    Isoniazid/vitamin B~6~ × 9 months                                       18 (90.0)                                                               42 (73.7)     60 (77.9)     0.38
    Rifampin × 4 months                                                     1 (5.0)                                                                 6 (10.5)      7 (9.1)       
    Rifampin/isoniazid/vitamin B~6~ × 6 months                              1 (5.0)                                                                 9 (15.8)      10 (13.0)     
  Medication delivery                                                                                                                                                           
    Directly observed treatment                                             9 (52.9)                                                                35 (61.4)     44 (59.5)     0.53
    Self-administered treatment                                             8 (47.1)                                                                22 (38.6)     30 (40.5)     
    Incentives used                                                         5 (27.8)                                                                18 (34.0)     23 (32.4)     0.63

Data presented as n (%) unless otherwise indicated.

n of each variable varies due to missing data;

Patients may have more than one reason for being offered LTBI
